TransCode Therapeutics shares are trading lower. The company announced Phase 1a dose escalation clinical trial update showing safety, tolerability, and disease stabilization with its lead candidate TTX-MC138.

Benzinga Newsdesk www.benzinga.com Positive 59.5%

Neg 0% Neu 0% Pos 59.5%

Comments

No comments yet. Be the first!